Friday, August 26, 2011

Cancer Comments

 (S)-2-Amino-3-(3-phenacetylimidazol-4-yl) propanoic acid

This new compound has reproducibly been independently confirmed as effective against all neoplasms tested :

ATCC U-87 ( Human Astrocytoma, Glioblastoma Multiforme )
ATCC HEP G2 ( Hepatocellular Carcinoma )
ATCC A-375 (Human Malignant Melanoma)

The Science... in detail (link)

This compound does not exhibit inhibition of normal 'healthy' B cells (D8 LCL B cells) - at concentrations used for inhibition of cancer.

This compound kills cancer cells.

Mechanism is consistent with induction of apoptosis - in neoplastic cells.

A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. 'chemo-brain', hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.
  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.

Finances are needed to finish the 'approval process' for this antineoplastic NCE:
CRO toxicology confirmation, IND/NDA filing with FDA, human clinical trials.
This is (and has been) ready! 

 Contributions, donations, investment.

Regards,

Dennis Wright
drwright442000@yahoo.com

Wednesday, August 24, 2011

Guest post - Rachel

Everything is coming up toxic and bad for you in cancer treatment! 
That is everything until NOW

This NCE (new chemical entity) developed by Scientist, Dennis Wright, is a non-toxic chemical used for cancer treatment.
In simple english, this chemical only attacks the cancer cells (when given in the proper doses), but leaves the 'normal/healthy' cells
untouched.  Hair is not lost - due to this treatment. "Chemo-brain" should not be a factor.  Any and all bad side-effects should
not be experienced when using this NCE for treatment of all cancers. 

So, instead of having patients face a treatment that is possibly worse than the disease itself, make them aware
of this NCE developed by Dennis Wright. 

Time to make this happen. Big voices and noises are needed to help move this along to the next stages so it
is available for near future use!

Rachel


http://diaryofadachshund.blogspot.com/

Thursday, August 11, 2011

Cancer Consequences... Article From http://diaryofadachshund.blogspot.com/

Just beyond the wall.

Living on earth, and living with what is available to us as a society:  I would say that is not always acceptable.
For many people looking for THE one thing that will help them, and they have found it, but it is not available.
What do you mean it is not available?
Take for instance, a TRUE STORY,  Emily:  We have permission to use her name from correspondence. She is a woman and a current patient fighting cancer.  Emily  has been in touch with a most important scientist and inventor, D.
D has developed  a novel compound that has been tested and proven to kill stubborn cancer, with no known side-effects on normal, healthy cells. It just works on the cancer cells by "making them commit suicide," is the best way to explain it.
Lady Emily is only looking to kick this cancer from her life. She has been healthy all of her life, that is until now.
Due to FDA guidelines, Lady Emily's best chances will be if she can be involved in the clinical trials. It may be some time before that can even occur. Earliest the trials may be held is in the Summer of 2011.   Until then, Emily and other people needing this to survive, have to do what they can to preserve their bodies and fight cancer the best they can.
What is great and somewhat, crazy, people have heard about D's great chemical compound. They want to have their hands on it TO LIVE. Here are excerpts  ( with permission granted from D) from an e-mail written by  Emily to inventor D:

I heard about your research from my cousin who is a nurse.  I had no idea I would ever possibly be talking to you.  The word "on the street" is that you are using amino acids to cure cancer but that your clinical trials won't be starting until next year.   Unfortunately I don't have that long to wait.

I had a tumor on my L4 and 11 lesions on my liver as of Sept 8.  I had 10 treatments of radiation on my back and that tumor is dead.  I then had 3 courses of chemo, Gemzarine and Taxotere which did absolutely nothing for my liver, I now have numerous lesions so this is a fairly aggressive cancer.

 I am very interested if you think you can help me, I was extremely healthy until this hit.  I didn't even have any symptoms from the liver.  If it hadn't have been for the tumor on my back, I wouldn't even know there was a problem.



So you can see how troubled the situation can be. Here we have a legitimate person reaching out to the actual inventor of her potential cure. D writes back very carefully and concerned. One less person in the the world dying from cancer that he may be able to help. Is there enough time? Here is a brief excerpt of a response from D :

I have been and continue to advance the 'state-of-the-art'.  With sufficient funding,  this new class of alpha amino acids can be in human clinical trials as soon as Summer 2011. This is all about timing and finances. Yes, many lives will be saved and many more will be spared the consequences of a cancer diagnosis.

So, D and Emily must wait for finances and timing. FINANCES AND TIMING!!!
If I knew there was a cure for MY cancer on the other side of the wall, I would grab a hammer and knock down the wall.  If I knew there was a cure for childhood cancer, breast cancer, ANY CANCER, I would do what I can.  D and Emily are doing what they can.
I call it "hurry up and wait."  We are stuck on one side of the river folks, a big and wide, treacherous river. On the other side of that river is THE CURE. Do you want to just have THE CURE sit on a shelf and watch others die needlessly? OR do you want to build that bridge with the finances and manpower needed to make us all see cancer vanish?  I am all about team work. Let us all find a way to do this.
We all know an Emily, and we want that person to succeed at beating cancer.
I like Emily and and want for her to survive happily.
I want inventor D to be successful and make other novel compounds to make life better for all of us.
Let's stop the walls from being in the way and knock them down. Let's build that bridge so that we may all share in knowing we've helped as best we can to eradicate cancer.

Monday, August 8, 2011

AminoGen Systems, Inc.

AminoGen Systems, Inc.

Contact:  Keith Hamilton                                                              
Tel: (609) 954 2709
E-mail: keithvha@verizon.net

BIOTECH COMPANY’S LIFE-CHANGING CHEMICAL READY FOR NEXT PHASE TESTING
Non-Toxic Cancer Drug Needed To Fight All Forms Of Cancer 
(Patent Pending)

'Pure science' is what it is taking to defeat cancer.  AminoGen Systems, Inc. is rapidly moving science to the next phase.  AminoGen Systems, Inc.  is working diligently to keep the ball rolling.  What they do need to make it to the next step of the process is FUNDING. Funding will advance the process of obtaining CRO toxicology,  IND/NDA filing,  and get this new chemical entity into human clinical trials.
AminoGen Systems, Inc. knows that science is not complete without the help of solid investors willing to make medical history ... and yes, every contribution and donation helps.

With funding  - we change the world! Those afflicted with cancer will have a non-toxic alternative to the common and  toxic chemotherapy / radiation therapy -  that often makes the “treatment” worse than the actual disease. 
AminoGen Systems, Inc. is a biotech company offering new chemical entities, research assistance, and consulting for the medical community at large. 

###
For information regarding AminoGen Systems 
Cancer Drugs, 
Financial Contributions, 
Donations and/or Investment Opportunities -
Contact : Mr. Keith Hamilton at (609) 954-2709 
E-mail Keith at:  keithvha@verizon.net


Friday, August 5, 2011

Hope... And Reality

 Several items to consider:


1.)  Currently, cancer victims who are refractile to chemotherapy and radiation therapy have limited options - (palliative care). 
This fact makes moot the argument to aggressively pursue treatment - the side effects are as detrimental as the disease.
*****
2.)   Independent testing has confirmed utility with difficult to treat cancer cell lines (U-87 [Astrocytoma, Glioblastoma Multiforme], HEP G2 [Hepatocellular Carcinoma], A 375 [Human Malignant Melanoma]).
Animal testing (mice), has shown no adverse effects - at concentrations thousands of times higher than used for in vitro testing.
*****
3.)   The benefits of commercial development of the NCE's outweigh all perceived risks. 
Independent verification of claims is a straightforward process... There is no downside. In addition to the preferred usage with oncology, these compounds are new chemical entities - specifically - novel alpha amino acids - which have demonstrated antibiotic utility.
*****
4.)   At present, the state-of-the-art regimen for aggressive cancer treatment involve combinations of  surgical excision, chemotherapy, radiation therapy. 
The compound, (S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid,  may eliminate the need for all of these.
*****
5.)  There are 208 separate and distinct cancers. 
The above points suggest a new compound which has potential for therapeutic treatment (primary, combination, adjuvant, prophylactic) of most, if not all, cancers - with no adverse side effects.
*****

The Science

A novel small molecule, alpha amino acid, antineoplastic - no demonstrated toxicity to 'healthy tissue'.
No anticipated 'side-effects' (e.g. hair-loss, hypernatremia, gastro-intestinal upset, nausea, somnolence).
Wide therapeutic margin.
Possible primary therapy, combination therapy, adjuvant therapy,  'compassionate use' therapy, possible prophylactic/maintenance therapy.
Excellent likelihood for good stability (and thus long shelf life).
Ease of use and administration - with oral dosing possible.
Low cost of goods.
Antibiotic properties.
New 'reagent' - opens possibilities for all science.
Possible nutritional supplement usage.

Demonstrated mechanism consistent with apoptotic pathway activation - in neoplastic cells.
*****

By activating the apoptosis pathway in a cancer cell leading to the cell death, this compound can be used to treat cancer of any type or origin, such as but not limited to adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma or teratocarcinoma, or the cancer of adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid or uterus.
*****
The science is independently confirmed, reproducible and undisputed... the impediment for this cure is  funding to advance the approval process (CRO toxicology, IND/NDA, human clinical trials). And, yes, it is rewarding to know this compound will save lives.

Regards,

Dennis Wright
drwright442000@yahoo.com

Wednesday, August 3, 2011

Mesothelioma... guest article


What is Mesothelioma?


Unlike other forms of cancer, Mesothelioma, is not as widely known.  Between 2000 and 3000 people are diagnosed with this rare form of cancer each year in the United States.  It is known to be a silent killer because it is so difficult to diagnose.  Many of those who are affected generally don’t experience symptoms for 20 to 50 years after their initial exposure.  The latency period can last several decades; and, by the time symptoms are apparent, it is often times too late.  Since the symptoms related to mesothelioma are very similar to those of other conditions, it is often times misdiagnosed or overlooked.

As previously mentioned, the latency period causes many potential problems for accurate diagnosis.  The reason for this latency period is due to the fact that many people were exposed to asbestos before the 80’s.  Asbestos laced products were heavily used in the military, construction, automobile industry, asbestos mining and processing plants, as well as residential areas.  Mesothelioma is primarily found in the lungs and/or abdomen.  In some instances, the likelihood for cancer in other areas of the body can increase.  Asbestos exposure occurs when microscopic asbestos fibers are inhaled and ingested.  These fibers then attach to the mesothelial lining of the lungs and, over time, can develop into cancerous tumors. 

For those who have been diagnosed with Mesothelioma, the prognosis is rather grave.  There are various factors that impact the mesothelioma prognosis; for example, how early it is detected, the type of mesothelioma, the overall health of the person, size/location of the tumor, and the stage of mesothelioma.  There are four stages of mesothelioma; Stage 1 describes the tumor as confined and does not involve the lymph nodes, Stage 2 has the tumor confined and the lymph nodes are involved, Stage 3 the tumor has penetrate past its confinement and involve the lymph nodes, Stage 4 is the most advance and least optimistic with the tumor fully metastasized into other parts of the body.

Unfortunately, there is no cure for mesothelioma; however, there are steps that can be taken in hopes to improve the prognosis associated with this cancer.  Many of those affected have undergone chemotherapy, radiation therapy, clinical trials, and even surgery.

We offer a variety of resources for mesothelioma patients and their families at The Mesothelioma Center.  Our wonderful Patient Advocates are available to assist with any questions you may have.  We also offer a Doctor Match program in which we are able to introduce you to doctors and suggest treatment centers for your specific diagnosis.  If you would like more information about mesothelioma, asbestos, or other asbestos related disease please feel free to visit: http://www.asbestos.com. http://twitter.com/TheMesoCenter http://www.facebook.com/themesocenter

Tuesday, August 2, 2011

(S)-2-Amino-3-(3-phenylacetylimadazol-4-yl)propanoic acid

  • Rapid inhibition of difficult to treat cancer cell lines.
  • Reproducible cell viability/dose response curves.
  • Mechanism consistent with activation of apoptotic pathway.
  • Physico-chemical properties consistent with high oral absorption and BBB (Blood-brain barrier) permeability.
  • Pharmacokinetics, ADME (Absorption, Distribution, Metabolism, Excretion), likely simple and efficient.
  • Metabolism most probably through decarboxylation.
This new chemical entity (NCE) has been independently confirmed as effective against U-87 cell line (brain cancer, anaplastic astrocytoma - glioblastoma multiforme), HEP G2 cell line (liver cancer, hepatocellular carcinoma), A 375 cell line (human malignant melanoma). A wide therapeutic margin with no inhibition of D8 LCL 'B' cells (control - 'normal' bone marrow) - at concentrations used to inhibit neoplasms. There are 208 individual types of cancer - this compound is effective against all three types listed above and will most probably be effective against the remaining 205.

CRO toxicology, pre-IND meeting with FDA, human clinical trials (Phase I or Phase I/II hybrid) - as soon as $$$ are available. Let's save lives!
Contact me if you can be of assistance with finances to expedite this process. Thank you.

Regards,

Dennis Wright
drwright442000@yahoo.com




Metastasis

Apoptosis

Monday, August 1, 2011

Advancing the 'state of the art'...

Currently, I am sourcing financing for toxicology testing and human clinical trials - for the new chemical entity, (S)-2-Amino-3-(3-phenylacetylimidazol-4-yl)propanoic acid. The anticipated timeline, here in the USA, will involve a complete toxicology study by a CRO (contract research organization), a pre-IND meeting with the FDA and subsequent human clinical trials (Phase I or a Phase I/II hybrid). If I can find sufficient finances soon - then it is possible to be in human clinical trials as soon as toxicology data is available (approximately six months or less). I anticipate early FDA approval - once the compound has been independently confirmed as 'non-toxic' to healthy tissue. This compound has a wide therapeutic margin and I anticipate utility against most, if not all, neoplasms. Antibiotic indications have also been demonstrated.

I do not concern myself with the 'politics' of pharmaceutical empires, rather, my efforts are directed at advancing the 'state of the art'. The science is undisputed... the impediment, at present, is securing adequate finances to advance the 'process'. And, yes, it is rewarding to know this compound will save lives.

How Cancer Develops

Cancer Scientist Dennis Wright (Applied Molecular Biologist, Biochemist, Chemical Engineer)

Most if not all of us have had at least one member of our immediate or extended family struck down by the insidious disease known as cancer.  We have been accustomed to organizations raising funds to promote cancer research but we have been similarly accustomed to never hearing that a cure has been discovered.  Cancer treatments to date all seem to follow one of three traditional courses; surgery to cut the tumor out, radiation to attempt to burn it into submission, or chemotherapy to poison the offending cells.  Recently, there has been some scientific/medical discussion about more targeted therapies and about drugs that may hold off the rapidly regeneration of cancer cells to extend one's life expectancy.

Mr. Wright has been intellectualizing his thoughts and concepts for a new cancer cure for over 5 years.  He took those thoughts into his lab over 3 years ago and invented a completely new class of alpha amino acids.  The resulting compound was successfully tested in Wright's lab against brain cancer cell lines, causing an apoptotic cascade (essentially causing the cancer cells to commit suicide).  Thereafter he did dosing experiments on mice and found that doses thousands of times higher than those used to stop the cancer cells, were still not toxic to mice.

Update from Dennis Wright - Biotech, Biochemical Expert


Scientific research is my life’s work.  Although I've many successes and achieved about 25 issued biotech patents, this project is the highlight of my professional career.  Each of my patents is like a child to me but this one appears more important than all:
 This new compound, or new chemical entity (NCE) has more potential applications, (antineoplastic, antiviral, antibiotic) and worldwide life-saving implications  than all of my previous inventions.
Greetings. I am the inventor of a novel class of compounds (paradigm shifting approach for treatment of neoplastic conditions). Independent confirmation of results with demonstrated utility for brain cancer (U-87), liver cancer (HEP G2), melanoma (A 375). 

I am and have been looking for funding in order to proceed to CRO toxicology, IND/NDA submission, FDA human clinical trials. The 'pre-clinical' utility has been amply demonstrated and with funding - this can be in Phase I / II trials in approximately six months. Kindly contact me if you are interested or can be of assistance sourcing finances to continue this endeavor. I look forward to your early reply. Thank you.

Regards,
Dennis
drwright442000@yahoo.com